These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 9181646

  • 21. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
    Lancet; 1999 Jun 12; 353(9169):2014-25. PubMed ID: 10376616
    [Abstract] [Full Text] [Related]

  • 22. Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
    Raboud JM, Montaner JS, Rae S, Kahn J, Hammer SM, Katzenstein DA, Pavia A, Dolin R, Hughes MD, Cross A, Beltangady M, Gatell J, Dunkle L, Smaldone L.
    Antivir Ther; 1997 Dec 12; 2(4):237-47. PubMed ID: 11327443
    [Abstract] [Full Text] [Related]

  • 23. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team.
    Currier JS, Spino C, Grimes J, Wofsy CB, Katzenstein DA, Hughes MD, Hammer SM, Cotton DJ.
    J Acquir Immune Defic Syndr; 2000 Aug 01; 24(4):316-24. PubMed ID: 11015147
    [Abstract] [Full Text] [Related]

  • 24. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
    Crespo M, Ribera E, Suárez-Lozano I, Domingo P, Pedrol E, López-Aldeguer J, Muñoz A, Viladés C, Sánchez T, Viciana P, Teira R, García-Alcalde ML, Vergara A, Lozano F, Galindo MJ, Cosin J, Roca B, Terrón A, Geijo P, Vidal F, Garrido M, VACH Cohort Study Group.
    J Antimicrob Chemother; 2009 Jan 01; 63(1):189-96. PubMed ID: 18988678
    [Abstract] [Full Text] [Related]

  • 25. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, Brouwers P, Mitchell WG, Yogev R, Wara DW, Wiznia A, Mofenson L, McNamara J, Spector SA.
    J Pediatr; 1998 Oct 01; 133(4):500-8. PubMed ID: 9787687
    [Abstract] [Full Text] [Related]

  • 26. Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group.
    d'Arminio Monforte A, Musicco M, Galli M, Paga C, La Regina A, Lazzarin A, Angarano G, Milazzo F, Gritti F, Arlotti M, Mazzotta F, Visco G, Aiuti F, Moroni M.
    Eur J Clin Microbiol Infect Dis; 1997 Feb 01; 16(2):135-42. PubMed ID: 9105840
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.
    AIDS; 2000 Jul 28; 14(11):1601-10. PubMed ID: 10983647
    [Abstract] [Full Text] [Related]

  • 29. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
    Kojima E, Shirasaka T, Anderson BD, Chokekijchai S, Steinberg SM, Broder S, Yarchoan R, Mitsuya H.
    J Infect Dis; 1995 May 28; 171(5):1152-8. PubMed ID: 7751690
    [Abstract] [Full Text] [Related]

  • 30. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
    Lancet; 1996 Aug 03; 348(9023):283-91. PubMed ID: 8709686
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, Jeffries D, Kaye S, Krzyanowski C, Nunn A, Schuurman R, Seigneurin JM, Tamalet C, Tedder R, Weber J, Weverling GJ.
    Lancet; 1997 Oct 04; 350(9083):983-90. PubMed ID: 9329513
    [Abstract] [Full Text] [Related]

  • 34. [Efficacy of combining zidovudine plus didanosine in patients with and without previous exposure to zidovudine].
    Gómez-Cano M, Soriano V, García-Lerma G, González-Lahoz J.
    An Med Interna; 1998 Mar 04; 15(3):145-7. PubMed ID: 9567422
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
    Conway B, Wainberg MA, Hall D, Harris M, Reiss P, Cooper D, Vella S, Curry R, Robinson P, Lange JM, Montaner JS.
    AIDS; 2001 Jul 06; 15(10):1269-74. PubMed ID: 11426071
    [Abstract] [Full Text] [Related]

  • 38. Maintaining a low viral load with Nevirapine?
    TreatmentUpdate; 1998 Dec 06; 10(10):3-4. PubMed ID: 11366017
    [Abstract] [Full Text] [Related]

  • 39. Data and safety monitoring in the Delta trial.
    Armitage P.
    Control Clin Trials; 1999 Jun 06; 20(3):229-41. PubMed ID: 10357496
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.